Teva Pharmaceuticals USA Faces Class II Recall for Subpotent Amoxicillin and Clavulanate Potassium Suspension
Teva Pharmaceuticals USA, Inc. has initiated a Class II recall for 4,680 cartons of Amoxicillin and Clavulanate Potassium for Oral Suspension due to subpotent Clavulanate Potassium. This voluntary, firm-initiated action, impacting Mississippi, Ohio, and California, necessitates immediate review by procurement and regulatory teams to assess supply chain integrity and potential product shortages for this critical antibiotic.
FDA Initiates Class II Recall for Subpotent Amoxicillin and Clavulanate Potassium Suspension
The U.S. Food and Drug Administration (FDA) has classified a voluntary recall initiated by Teva Pharmaceuticals USA, Inc. as Class II, signaling a situation where the use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This specific recall, identified as D-0151-2026, targets Amoxicillin and Clavulanate Potassium for Oral Suspension USP, 200 mg/28.5 mg per 5mL, 100 mL (when reconstituted), an Rx-only product. The critical issue identified is that the Clavulanate Potassium component of the drug product was found to be subpotent. For procurement directors and regulatory affairs heads, this means that the efficacy of the antibiotic combination could be compromised, potentially leading to treatment failures for patients relying on this medication. The affected product is from Lot # 100062316, with an expiration date of January 2026, and carries the NDC 0093-2277-7. The recall was initiated by Teva Pharmaceuticals USA, Inc. on October 13, 2025, with the FDA classifying it on November 3, 2025. This event underscores the imperative for robust quality control throughout the manufacturing process, particularly for active pharmaceutical ingredients (APIs) where precise potency is paramount for therapeutic effect.
Teva's Operational Footprint and Immediate Distribution Impact
The recalled Amoxicillin and Clavulanate Potassium for Oral Suspension was manufactured in Canada by Teva Canada Limited, located in Toronto, Canada M1B 2K9, and subsequently manufactured for Teva Pharmaceuticals USA, Inc., based in Parsippany, NJ 07054. This cross-border manufacturing and distribution model highlights the complexities inherent in global pharmaceutical supply chains. A total of 4,680 cartons of the affected product were distributed across three U.S. states: Mississippi (MS), Ohio (OH), and California (CA). For supply chain VPs and business development executives, this specific distribution pattern means immediate action is required within these states to identify and quarantine affected stock. The quantity of 4,680 cartons represents a tangible disruption to the supply of a commonly prescribed antibiotic in these regions. Businesses operating in or supplying to MS, OH, and CA must promptly assess their inventory, distribution networks, and customer notifications to ensure compliance with the recall and minimize further exposure to the subpotent product. The firm-initiated nature of the recall indicates Teva's proactive identification of the issue, but the subsequent Class II classification by the FDA emphasizes the potential health implications and the need for swift, coordinated action across the supply chain.
Commercial and Therapeutic Risks of Clavulanate Potassium Subpotency
The subpotency of the Clavulanate Potassium component in Teva's Amoxicillin and Clavulanate Potassium for Oral Suspension carries significant commercial and therapeutic risks. Clavulanate Potassium is crucial in this combination antibiotic, as it acts as a beta-lactamase inhibitor, protecting amoxicillin from degradation by bacterial enzymes and thereby extending its spectrum of activity. A subpotent level means that the protective effect is diminished, potentially rendering the amoxicillin ineffective against resistant bacterial strains. For healthcare providers, this translates to a risk of treatment failure, prolonged illness, and the potential for adverse patient outcomes. For pharmaceutical distributors and pharmacies, the commercial implications are substantial. Distributing or dispensing a subpotent drug can lead to reputational damage, customer distrust, and potential liability issues, irrespective of whether the firm initiated the recall. Business development executives must consider the broader market perception of product quality and reliability when sourcing such critical medications. This incident underscores the absolute necessity for rigorous quality assurance and control measures at every stage of the pharmaceutical lifecycle, from API synthesis to final product release, to safeguard both patient health and commercial integrity.
Regulatory Compliance and Firm-Initiated Remediation
The recall is currently classified as "Ongoing" by the FDA, indicating that Teva Pharmaceuticals USA, Inc. is actively engaged in the recall process, which typically involves identifying affected product, notifying customers, and managing returns. As a voluntary, firm-initiated recall, Teva has taken the initial step to address the issue. However, the FDA’s Class II classification mandates a specific level of scrutiny and action. For regulatory affairs heads, this means Teva is expected to conduct a thorough investigation into the root cause of the Clavulanate Potassium subpotency, implement comprehensive corrective and preventive actions (CAPA), and provide regular updates to the FDA. Failure to adequately address the underlying quality system deficiencies could lead to further regulatory actions, including potential Warning Letters or increased inspection frequency. Procurement directors should monitor the progress of this recall closely, as the remediation efforts and their effectiveness will dictate the long-term reliability of Teva as a supplier for this critical product. This event serves as a critical reminder for all pharmaceutical companies to maintain robust quality management systems that can detect and prevent such potency issues before products reach the market, thereby mitigating significant regulatory and commercial fallout.
Strategic Implications for Pharmaceutical Procurement and Quality Assurance
This Class II recall by Teva Pharmaceuticals USA, Inc. for a subpotent antibiotic carries significant strategic implications for procurement directors and quality assurance heads across the global chemical and life sciences industry. The incident highlights the inherent risks associated with active pharmaceutical ingredient (API) quality, particularly for combination products where the potency of each component is critical to therapeutic efficacy. Businesses must re-evaluate their supplier qualification programs, ensuring that robust analytical testing protocols are in place for incoming raw materials and finished products. Relying solely on Certificates of Analysis (CoAs) from manufacturers may not be sufficient; independent verification of critical parameters like potency is a prudent risk mitigation strategy. Furthermore, supply chain VPs should consider diversifying their sourcing strategies for essential medicines like Amoxicillin and Clavulanate Potassium to reduce dependence on a single manufacturer or geographic region. This proactive approach can buffer against potential supply disruptions stemming from quality issues or regulatory actions. The Teva recall serves as a tangible case study, emphasizing that vigilance in quality assurance and strategic procurement planning are not merely compliance exercises but fundamental pillars of business continuity and patient safety in the pharmaceutical sector.